Our prior findings indicate that pancreatic cancer cells sensitive to EGFR-targeted therapy can be rendered resistant via siRNA-induced ErbB3 inhibition, which suggests a critical influence of ErbB3 in pancreatic cancer EGFR signalling (Frolov et al, 2007). This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.